Tympanogen, Inc.

Tympanogen, Inc. develops innovative solutions for ear, nose, and throat (ENT) specialists, focusing on advanced treatment options that enhance patient care and improve surgical outcomes in the field of otology. Founded in 2014 and headquartered in Richmond, US, Tympanogen, Inc. creates medical solutions aimed at transforming the repair of eardrum perforations.

The company was established by Elaine Horn-Ranney, Gary Gagstetter, and Parastoo Khoshakhlagh. In total, it has completed 7 funding deals, with the most recent being a Series A round in February 2025, where it raised USD 1. 156 mn, bringing its total amount raised to USD 1. 156 mn and its current valuation to USD 33.

159 mn. Tympanogen specializes in innovative solutions for ear, nose, and throat (ENT) surgeons, primarily through its flagship product, Perf-Fix™, an otologic gel patch designed for nonsurgical eardrum repair. This novel gel system aims to replace traditional tympanoplasty, enabling a clinic-based procedure that allows for outpatient care. The Perf-Fix™ product addresses key challenges in tympanic membrane perforations, providing increased efficiency for clinicians and improved patient experiences through rapid healing and high-quality regeneration without the need for surgery.

The company targets ENT practitioners and healthcare facilities across the United States, with aspirations to expand into international markets, enhancing access to advanced outpatient ENT care and transforming how ear-related conditions are treated. Tympanogen's revenue model is primarily based on direct transactions with healthcare providers, particularly ENT clinics and outpatient facilities that require advanced treatment options for eardrum repairs. The company’s key product, Perf-Fix™, will be marketed through direct sales and partnerships with medical distributors specializing in ENT solutions, thus ensuring a streamlined supply chain. Pricing strategies for Perf-Fix™ are structured to reflect its unique benefits in outpatient settings, particularly in improving workflow efficiency and patient outcomes.

The company is positioned to capitalize on the growing demand for minimally invasive treatments in the healthcare sector, reinforcing its commitment to providing transformative care through innovative technology. In February 2025, Tympanogen, Inc. raised USD 1. 16 mn in Series A funding from an unspecified investor.

The company plans to utilize this funding to enhance the development and marketing of its flagship product, Perf-Fix™, and to explore the introduction of new products aimed at various aspects of ENT care. Additionally, Tympanogen is targeting international markets for expansion, with specific plans to enter regions in Europe and Asia by 2026, thereby increasing access to their innovative solutions and establishing a broader footprint in the global healthcare landscape.